AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the ...

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...

AbbVie ABBV announced that the phase III VERONA study failed to meet the primary endpoint of overall survival. The study ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Roche and AbbVie have come up short again in their effort to gain an additional indication for their blockbuster blood cancer ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

Venclexta (venetoclax) is a prescription drug that’s used to treat certain blood cancers. Venclexta comes as an oral tablet. Venclexta is used in adults to treat the following cancers in certain ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Learn about Venclexta’s common, mild, and serious side effects and how to manage them. Venclexta (venetoclax) is a prescription drug used to treat acute myeloid leukemia (AML) and other cancers.

Venclexta (venetoclax) is a brand-name oral tablet prescribed for certain types of cancer in adults. As with other drugs, Venclexta can cause side effects, such as nausea, fatigue, or dizziness.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...